• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对依托泊苷和顺铂的异常良好反应。

An Exceptionally Favorable Response to Etoposide and Cisplatin.

作者信息

Valecha Gautam, Vennepureddy Adarsh, Ibrahim Uroosa, Odaimi Marcel

机构信息

Medicine, Staten Island University Hospital.

Hematology-Oncology, Staten Island University Hospital.

出版信息

Cureus. 2015 Dec 18;7(12):e418. doi: 10.7759/cureus.418.

DOI:10.7759/cureus.418
PMID:26848411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4725742/
Abstract

A 66-year-old female with multiple medical co-morbidities was diagnosed with limited-stage small cell lung carcinoma (SCLC) about 11 years ago, back in 2004. The patient was treated with concomitant chemotherapy and radiotherapy, along with prophylactic whole brain radiation. She received a total of four cycles of etoposide and cisplatin. The patient showed a complete response to the above-mentioned treatment and had no evidence of tumor recurrence on any of the scans until 2015. Her last computed tomography (CT) scan of the chest in October 2015 showed bilateral hilar and mediastinal lymphadenopathy. Fine needle aspiration (FNA) of the left hilar node revealed the presence of malignant cells consistent with SCLC. Median survival for limited stage SCLC ranges from 16-24 months, and the reported five-year survival is 14%. In this report, we present the case of a 66-year-old female who showed an exceptionally favorable response to cisplatin and etoposide chemotherapy characterized by a disease-free survival of 11 years.

摘要

一位患有多种合并症的66岁女性大约在11年前，即2004年被诊断为局限期小细胞肺癌（SCLC）。该患者接受了同步化疗和放疗，以及预防性全脑放疗。她总共接受了四个周期的依托泊苷和顺铂治疗。患者对上述治疗显示出完全缓解，直到2015年的任何扫描中均无肿瘤复发迹象。她在2015年10月的最后一次胸部计算机断层扫描（CT）显示双侧肺门和纵隔淋巴结肿大。左肺门淋巴结细针穿刺（FNA）显示存在与SCLC一致的恶性细胞。局限期SCLC的中位生存期为16 - 24个月，报道的五年生存率为14%。在本报告中，我们介绍了一例66岁女性，她对顺铂和依托泊苷化疗表现出异常良好的反应，无病生存期达11年。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/0a5141c10597/cureus-0007-000000000418-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/9ddb6213a57e/cureus-0007-000000000418-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/06fe0ec694b4/cureus-0007-000000000418-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/6fa27f7e235b/cureus-0007-000000000418-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/a94f3a0e4a6e/cureus-0007-000000000418-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/0a5141c10597/cureus-0007-000000000418-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/9ddb6213a57e/cureus-0007-000000000418-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/06fe0ec694b4/cureus-0007-000000000418-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/6fa27f7e235b/cureus-0007-000000000418-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/a94f3a0e4a6e/cureus-0007-000000000418-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9922/4725742/0a5141c10597/cureus-0007-000000000418-i05.jpg

相似文献

1
An Exceptionally Favorable Response to Etoposide and Cisplatin.对依托泊苷和顺铂的异常良好反应。
Cureus. 2015 Dec 18;7(12):e418. doi: 10.7759/cureus.418.
2
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.依托泊苷和顺铂与伊立替康和顺铂在接受依托泊苷和顺铂联合同期加速超分割胸部放射治疗的局限期小细胞肺癌患者中的比较（JCOG0202）：一项随机 3 期研究。
Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3.
3
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.顺铂-依托泊苷与拓扑替康交替用于广泛期小细胞肺癌（SCLC）患者。一项多中心II期研究。
Lung Cancer. 2002 Oct;38(1):59-63. doi: 10.1016/s0169-5002(02)00149-6.
4
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.紫杉醇、依托泊苷和顺铂化疗联合每日两次胸部放疗治疗局限期小细胞肺癌患者的研究：放射肿瘤学组9609 II期研究
J Clin Oncol. 2005 Aug 1;23(22):4991-8. doi: 10.1200/JCO.2005.00.414. Epub 2005 Jun 6.
5
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.伊立替康联合顺铂诱导化疗后，同步每日两次胸部放疗并联合依托泊苷加顺铂化疗用于局限期小细胞肺癌的II期研究。
J Clin Oncol. 2005 May 20;23(15):3488-94. doi: 10.1200/JCO.2005.01.082.
6
Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).顺铂同步、口服依托泊苷延长疗程、长春新碱联合胸部及脑部放疗用于局限期小细胞肺癌：西南肿瘤协作组（SWOG-9229）的一项II期研究
Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1039-47. doi: 10.1016/s0360-3016(98)00003-0.
7
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.100例小细胞肺癌患者使用标准剂量和高剂量依托泊苷、异环磷酰胺、卡铂及表柔比星的研究：一项成熟的随访报告
Ann Oncol. 1999 May;10(5):561-7. doi: 10.1023/a:1026453922931.
8
Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.顺铂、依托泊苷与放疗同步治疗不可切除的Ⅲ期非小细胞肺癌：一项Ⅱ期研究。
Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):343-50. doi: 10.1016/0360-3016(96)00087-9.
9
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.对100例连续的局限性和广泛性小细胞肺癌患者采用依托泊苷、异环磷酰胺、顺铂和表柔比星进行剂量密集治疗（VIP-E方案）。
Ann Oncol. 1997 Jan;8(1):49-56. doi: 10.1023/a:1008232329498.
10
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.顺铂、依托泊苷和贝伐单抗方案序贯口服依托泊苷和贝伐单抗维持治疗广泛期小细胞肺癌患者：单机构经验
Clin Lung Cancer. 2015 Nov;16(6):e229-34. doi: 10.1016/j.cllc.2015.05.005. Epub 2015 May 18.

本文引用的文献

1
Long-term survival in small cell lung cancer: a case report and review of the literature.小细胞肺癌的长期生存：一例病例报告及文献综述
Future Oncol. 2014 Mar;10(4):523-8. doi: 10.2217/fon.13.213.
2
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.一名小细胞肺癌患者在接受九线化疗和放疗后长期存活。
Onkologie. 2008 Sep;31(8-9):469-72. doi: 10.1159/000142396. Epub 2008 Aug 15.
3
Long-term survival of a patient with small cell lung cancer associated with cancer-associated retinopathy.
Lung Cancer. 2007 Sep;57(3):399-403. doi: 10.1016/j.lungcan.2007.02.015. Epub 2007 Mar 29.
4
Relapse of stage I small cell lung cancer ten or more years after the start of treatment.
Jpn J Clin Oncol. 2006 Jul;36(7):457-61. doi: 10.1093/jjco/hyl044. Epub 2006 Jun 16.
5
Ten years of disease-free survival between two diagnoses of small-cell lung cancer: a case report and a literature review.两次小细胞肺癌诊断之间十年的无病生存期：一例病例报告及文献综述
Med Oncol. 2005;22(1):89-97. doi: 10.1385/MO:22:1:089.
6
Redevelopment of small cell lung cancer after a long disease-free period: a case report.
Jpn J Clin Oncol. 2002 Jan;32(1):30-2. doi: 10.1093/jjco/hyf008.
7
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.小细胞肺癌的长期生存：存活5至18年以上患者的治疗后特征——对1714例连续患者的分析
J Clin Oncol. 1995 May;13(5):1215-20. doi: 10.1200/JCO.1995.13.5.1215.
8
The incidence of second primary tumors in long-term survivors of small-cell lung cancer.
J Clin Oncol. 1992 Oct;10(10):1519-24. doi: 10.1200/JCO.1992.10.10.1519.